Mobile Health Tool May Improve Quality of Life for Adolescent and Young Adult Breast Cancer Survivors
SAN ANTONIO – A mobile health (mHealth) intervention for adolescent and young adult breast cancer survivors that offered tailored...
Search/Filter
Loading...
Acupuncture May Help Improve Perceived Breast Cancer-related Cognitive Difficulties Over Usual Care
SAN ANTONIO – Real and sham acupuncture were more effective at improving breast cancer survivors’ perceived cognitive impairment compared...
Preoperative Radiation May Improve Antitumor Immune Response in Most Common Form of Breast Cancer
SAN ANTONIO – Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when...
Breast MRI May Be Safely Omitted From Diagnostic Workup in Certain Patients With Early-stage, HR-negative Breast Cancer
Preoperative MRI had no impact on five-year recurrence rates SAN ANTONIO – Patients with stage 1 or 2, hormone...
Sentinel Lymph Node Biopsy May Be Safely Omitted in Some Patients With Early-stage Breast Cancer
Omission of sentinel lymph node biopsy did not change five-year recurrence rates SAN ANTONIO – Skipping sentinel lymph node...
A Multimodal AI Model May Improve Recurrence Risk Stratification in Early Breast Cancer
New model provided better prognostic information for recurrence in HR-positive, HER2-negative breast cancer than the Oncotype DX 21-gene recurrence...
Sacituzumab Govitecan-hziy Led to Similar Progression-free Survival as Standard of Care for Certain Endocrine Therapy-refractory Advanced Breast Cancers
SAN ANTONIO – Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they...
Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial
Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to...
Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial
SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant...
AACR Releases Inaugural Pediatric Cancer Progress Report
More than 30 new drugs have been approved for pediatric cancer in the past 10 years, but progress has...